AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16454979
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (loading dose of 300 mg aspirin, then 100 mg per day)
Trial: 16454979
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (30 healthy volunteers on no medications)
Trial: 8957697
Drug: Oral Vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Vitamin E treatment
Trial: 1533427
Drug: ANP value
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANP value greater than 200 pmol/L
Trial: 2410520
Drug: Thiazina (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazina (combination tablet of thiacetazone and INH) daily for 12 months
Trial: 2410520
Drug: Thiazina daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazina daily for 12 months plus rifampin daily during months 1 and 7
Trial: 2410520
Drug: Rifampin daily
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin daily during months 1 and 7 but no Thiazina
Trial: 2410520
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (dapsone monotherapy)
Trial: 12975409
Drug: Alpha blocker
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha blocker
Trial: 29094283
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for depression and anxiety
Trial: 27768695
Drug: CCX168 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCX168 (30 mg orally, twice daily)
Trial: 27768695
Drug: CCX168 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCX168 (1 to 100 mg)
Trial: 24456286
Drug: Teriparatide (TPT;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (TPT; 20 μg s.c.) for 6 months
Trial: 23321196
Drug: Tolvaptan 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan 3.75 mg/day
Trial: 23551935
Drug: Tolvaptan 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan 7.5 mg/day
Trial: 20837928
Drug: Atorvastatin 0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 0, 5, or 50 μmol/L ex vivo
Trial: 10440462
Drug: Gabapentin (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (900 to 3,600 mg daily in three divided doses)
Trial: 2276107
Drug: Oral care
RxNorm normalized name: Oral Care Q4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral care protocol A
Trial: 2276107
Drug: Oral care
RxNorm normalized name: Oral Care Q4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral care protocol B
Trial: 2276107
Drug: Reinforcement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinforcement of oral care instructions and nursing assessments
Trial: 22883421
Drug: Fentanyl 1
RxNorm normalized name: fentanyl 1.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1 mcg/kg
Trial: 22883421
Drug: Fentanyl 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 0.5 mcg/kg
Trial: 9931196
Drug: Acetaminophen (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (4 g/day)
Trial: 18534086
Drug: BIS 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS 0.5 mg twice daily (b.i.d.)
Trial: 18534086
Drug: BIS 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS 0.25 mg b.i.d. and 0.5 mg b.i.d.
Trial: 18534086
Drug: BIS 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS 0.25 mg once daily (q.d.)
Trial: 18534086
Drug: BIS 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS 0.5 mg q.d.
Trial: 18534086
Drug: BIS 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS 1.0 mg q.d.
Trial: 17242413
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion (CEI) of 0.2% ropivacaine hydrochloride (10 mL/h without bolus)
Trial: 17242413
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (10 mL of 0.2% ropivacaine hydrochloride per hour with 10-mL bolus)
Trial: 3190996
Drug: Soluble aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble aspirin 900 mg
Trial: 9545995
Drug: Risperidone (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (6 mg/day, adjusted to 6.4 mg/day)
Trial: 9545995
Drug: Clozapine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (300 mg/day, adjusted to 291.2 mg/day)
Trial: 11429337
Drug: Fenoldopam infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoldopam infusion
Trial: 2574081
Drug: Control infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control infusion (0.9% saline)
Trial: 7411761
Drug: Erythromycin stearate
RxNorm normalized name: Erythromycin Stearate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin stearate or estolate, 500 mg orally every six hours for five days (13 patients)
Trial: 7411761
Drug: Crystalline aqueous
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalline aqueous penicillin G potassium, 1 million units intravenously every three hours for three days (10 patients)
Trial: 31567921
Drug: Same-day dose
RxNorm normalized name: SAMe
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same-day dose of 4 L polyethylene glycol
Trial: 31567921
Drug: Split-dose of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose of 4 L polyethylene glycol (2 L at 9:00 PM the day before and 2 L at 7:00 AM or 10:00 AM)
Trial: 31567921
Drug: Split-dose of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose of 4 L polyethylene glycol
Trial: 12185558
Drug: Oral artemisinin
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral artemisinin 500 mg daily for 3 days followed by oral mefloquine 750 mg on day 4
Trial: 12185558
Drug: Oral artemisinin
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral artemisinin 500 mg daily for 3 days plus oral mefloquine 750 mg on day 1
Trial: 12185558
Drug: Single 750-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 750-mg oral dose of mefloquine
Trial: 12185558
Drug: Artemisinin and
RxNorm normalized name: artemisinin and piperaquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin and mefloquine combination
Trial: 9455524
Drug: Azithromycin, 250
RxNorm normalized name: Azithromycin, 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin, 250 mg daily
Trial: 9455524
Drug: Azithromycin, 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin, 1,000 mg weekly
Trial: 9455524
Drug: Doxycycline, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline, 100 mg daily
Trial: 1695877
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of terfenadine and flurbiprofen
Trial: 1695877
Drug: All active
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All active drug days (terfenadine, flurbiprofen, combination)
Trial: 320477
Drug: Antibiotics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics plus daily granulocyte transfusions from ABO-matched donors
Trial: 23422376
Drug: Intramuscular ziprasidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ziprasidone (10 to 20 mg as required up to a maximum of 40 mg/d)
Trial: 23422376
Drug: Intramuscular haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular haloperidol (5 mg every 4 to 8 hours to a maximum of 20 mg/d)
Trial: 20615933
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate (starting dose 50 mg eq., flexible dosing of 25, 50, 75, or 100 mg eq.)
Trial: 19439457
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg Fe with 400 microg folic acid
Trial: 19439457
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Fe with 400 microg folic acid
Trial: 19439457
Drug: Multiple micronutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrients (MuMS; 30 mg Fe, 400 microg folic acid, and other micronutrients)
Trial: 16460693
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day citalopram
Trial: 11680557
Drug: Combined individual
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined individual and family therapy
Trial: 9326834
Drug: Xanomeline (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanomeline (25 mg t.i.d., 50 mg t.i.d., 75 mg t.i.d.)
Trial: 8145176
Drug: Alprazolam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (1 mg decrease every 3-7 days)
Trial: 8145176
Drug: Alprazolam (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (long-term treatment for 5-12 months)
Trial: 8145176
Drug: Alprazolam (tapering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (tapering and discontinuation)
Trial: 2427808
Drug: 90 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg/day nicardipine for 2 weeks
Trial: 31405765
Drug: Vortioxetine 10
RxNorm normalized name: vortioxetine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine 10 mg QD for 5 weeks
Trial: 31405765
Drug: Vortioxetine 20
RxNorm normalized name: vortioxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine 20 mg QD for 5 weeks
Trial: 31405765
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg QD for 5 weeks
Trial: 23860985
Drug: Vasopressin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasopressin (20 IU/CPR cycle) plus epinephrine (1 mg/CPR cycle)
Trial: 23860985
Drug: Vasopressin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasopressin (20 IU/CPR cycle) plus epinephrine (1 mg/CPR cycle) with postresuscitation shock treatment of stress-dose hydrocortisone (300 mg daily for 7 days maximum)
Trial: 23860985
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo plus epinephrine (1 mg/CPR cycle)
Trial: 23860985
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo plus epinephrine (1 mg/CPR cycle) with postresuscitation shock treatment of saline placebo
Trial: 21523459
Drug: Standard postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard postoperative treatment group (B) - normal postoperative treatment or no treatment/self-management
Trial: 18295613
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy (30 minutes a day, 5 days a week for 4 weeks)
Trial: 14594886
Drug: Digoxin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (0.25 mg orally for 12 days)
Trial: 11079645
Drug: Short-term vitamin
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term vitamin C therapy (intravenous)
Trial: 11079645
Drug: Long-term vitamin
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term vitamin C therapy (oral)
Trial: 31846631
Drug: 12-week daily
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week daily meal with fresh Hass avocado
Trial: 21290836
Drug: Acupoint catgut
RxNorm normalized name: CATGUT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint catgut embedding therapy
Trial: 21528595
Drug: Pinaverium Bromide
RxNorm normalized name: pinaverium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinaverium Bromide (50 mg, 3 times a day for 30 days)
Trial: 19366490
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg x d DSR
Trial: 15293131
Drug: Tablet-based 13C-urea
RxNorm normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet-based 13C-urea breath test
Trial: 8295092
Drug: 0.15% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15% chlorhexidine digluconate solution
Trial: 8295092
Drug: Sodium benzoate-sodium
RxNorm normalized name: sodium benzoate-sodium phenylacetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium benzoate-sodium bicarbonate (SBSB) compound
Trial: 20651059
Drug: sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib 400 mg twice a day
Trial: 14506483
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g low-fat (40%) spread fortified with 200 microg FA and a placebo tablet
Trial: 14506483
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g low-fat placebo spread and a 200 microg FA tablet
Trial: 14506483
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g low-fat placebo spread and a placebo tablet
Trial: 10392865
Drug: High-dose recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose recombinant urokinase (350,000 IU/hour for 6 hours, then 125,000 IU/hour for up to 18 hours)
Trial: 10392865
Drug: Low-dose recombinant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose recombinant urokinase (125,000 IU/hour for 6 hours, then 125,000 IU/hour for up to 18 hours)
Trial: 10392865
Drug: High-dose recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose recombinant urokinase
Trial: 10392865
Drug: Low-dose recombinant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose recombinant urokinase
Trial: 10392865
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of recombinant urokinase
Trial: 9373124
Drug: Conventional dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dual therapy (gentamicin 1.5% and cefuroxime 5.0%)
Trial: 31492775
Drug: Strength training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength training intervention for hypogonadal patients with testosterone replacement therapy
Trial: 31492775
Drug: Strength training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength training intervention for newly diagnosed males without testosterone replacement therapy
Trial: 29980005
Drug: Single‐shot ultrasound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single‐shot ultrasound (US)‐guided ESP block with 20 ml 0.25% bupivacaine at the T4 vertebral level
Trial: 29980005
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups provided with intravenous patient‐controlled analgesia device containing morphine
Trial: 25364676
Drug: Hydrocortisone regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone regimen 1 (evening dose at 06.00-07.00 pm)
Trial: 25364676
Drug: Hydrocortisone regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone regimen 2 (evening dose at 09.00-10.00 pm)
Trial: 25364676
Drug: Prednisolone regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone regimen (evening dose at 10.00 pm)
Trial: 18705533
Drug: Telmisartan monotherapy
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan monotherapy (10-160 mg)
Trial: 18705533
Drug: Telmisartan plus
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan plus HCTZ (10-160 mg + 6.25-25 mg)
Trial: 18705533
Drug: Telmisartan monotherapy
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan monotherapy (open-label)
Trial: 12947329
Drug: Studies with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Studies with positive treatment effect
Trial: 10593790
Drug: Hypoxic gas
RxNorm normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoxic gas inhalation with aerosolized methacholine
Trial: 10593790
Drug: Normoxic gas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normoxic gas inhalation with aerosolized methacholine
Trial: 8722544
Drug: Erythromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (1 g)
Trial: 8722544
Drug: Clindamycin (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (0.6 g)
Trial: 6097818
Drug: Gyno‐Travogen® vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gyno‐Travogen® vaginal tablets (300 mg isoconazole nitrate each)
Trial: 6097818
Drug: Nizoral® tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizoral® tablets (200 mg ketoconazole each)
Trial: 27900987
Drug: CEE 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.3 mg/micronized progesterone (MP) 100 mg daily (Group A)
Trial: 27900987
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 mg/MP 100 mg daily (Group B)
Trial: 27900987
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 mg/dydrogesterone 10 mg daily (Group C)
Trial: 25248815
Drug: CRP levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP levels >3 mg/L
Trial: 25248815
Drug: CRP levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP levels <1 mg/L
Trial: 22763155
Drug: 800 IU
RxNorm normalized name: Vitamin E 800 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 IU of vitamin D3 (pills)
Trial: 20619140
Drug: Metoclopramide, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide, 20 mg intramuscularly injected three times a day.
Trial: 7577891
Drug: Maize-based weaning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maize-based weaning food (before amylase treatment)
Trial: 30171280
Drug: Cyclosporine 200
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine 200 mg + Eltrombopag 50 mg
Trial: 30171280
Drug: Cyclosporine 600
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine 600 mg + Eltrombopag 50 mg
Trial: 30171280
Drug: Eltrombopag 50
RxNorm normalized name: eltrombopag 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 50 mg alone
Trial: 23777441
Drug: Single 2.5 mg/0.1 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 2.5 mg/0.1 mL dose of subconjunctival bevacizumab immediately after surgery (group 1)
Trial: 23777441
Drug: Double 2.5 mg/0.1 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double 2.5 mg/0.1 mL injection of subconjunctival bevacizumab (one immediately after surgery and the second 15 days after surgery) (group 2)
Trial: 23777441
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No injection (group 3)
Trial: 12197843
Drug: Simethicone (105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simethicone (105 mg t.d.s.)
Trial: 26465985
Drug: Both vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vitamin D3 (1000 IU) and calcium (1200 mg)
Trial: 26465985
Drug: Placebo (neither
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (neither agent)
Trial: 20689455
Drug: Fruit, berry,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruit, berry, and vegetable concentrate (FVC), Juice Plus+® (NSA LLC, Collierville, TN), supplement
Trial: 19626400
Drug: Trimetazidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (20 mg three times per day)
Trial: 16422738
Drug: Structured reminiscence
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured reminiscence group sessions held twice weekly for a six-week period
Trial: 11700812
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 1 g
Trial: 11700812
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 3 g
Trial: 11700812
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 3 g with additives ('Bio-C')